High-dose steroid therapy for CNS inflammatory diseases increases INR in patients taking oral vitamin K antagonist

Stefano Gelibter; Mario Orrico; Tommaso Croese; Luca Bosco; Vittorio Martinelli; Francesca Sangalli; Massimo Filippi

doi:10.1007/s00415-019-09515-6

Back

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Article2019

Non–Vitamin K Antagonist Oral Anticoagulants in Asian Patients With Supranormal Renal Function

Seil Oh, Professor Gregory Lip, So-Ryoung Lee, Eue-Keun Choi, Kyungdo Han, Jin‐Hyung Jung, Myung‐Jin Cha

Article2016

Vitamin K and non-vitamin K antagonist oral anticoagulants for non-valvular atrial fibrillation in real-life

Michela Giustozzi, Maria Cristina Vedovati, Paolo Verdecchia, Lucia Pierpaoli, Melina Verso, Serenella Conti, F Cianella, Emanuela Marchesini, Esmeralda Filippucci, Giancarlo Agnelli, Cecilia Becattini

Article2019

Novel Oral Anticoagulant Based Versus Vitamin K Antagonist Based Double Therapy Among Stented Patients With Atrial Fibrillation

Mathieu Kernéis, Megan K. Yee, Roxana Mehran, Tarek Nafee, Christoph Bode, Jonathan L. Halperin, Eric D. Peterson, Freek W.A. Verheugt, Peter Wildgoose, Martin van Eickels, Professor Gregory Lip, Marc Cohen, Keith A.A. Fox, C. Michael Gibson

Article2022

Optimizing adherence and persistence to non-vitamin K antagonist oral anticoagulant therapy in atrial fibrillation

J Farinha, Ian Jones, Professor Gregory Lip

Article2022

Anticoagulation Control in Older Atrial Fibrillation Patients Receiving Vitamin K Antagonist Therapy for Stroke Prevention

Hanis Hanum Zulkifly, Professor Gregory Lip, Deirdre A. Lane